---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-096645"
form_type: "8-K"
ticker: "SABS"
cik: "0001833214"
company_name: "SAB Biotherapeutics, Inc."
filed_at: "2025-07-17T23:59:59+00:00"
generated_at: "2026-05-18T05:59:54.014592+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# SAB Biotherapeutics elects four Class I directors, ratifies auditor at 2025 annual meeting

## Summary
- Shareholders elected Dr. William Polvino, Scott Giberson, Erick Lucera, and Dr. Jay S. Skyler as Class I directors for three-year terms.
- Appointment of EisnerAmper LLP as independent auditor for fiscal year 2025 ratified with 6,374,363 votes for, 238,327 against.
- Quorum of 71.38% achieved; 6,633,125 shares present out of 9,291,697 outstanding.
- Broker non-votes of 2,154,677 on director elections; each director received over 4.3 million votes for.

## SEC filing metadata
- accession: 0000950170-25-096645
- form_type: 8-K
- ticker: SABS
- cik: 0001833214
- company_name: SAB Biotherapeutics, Inc.
- filed_at: 2025-07-17T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1833214/000095017025096645/0000950170-25-096645-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1833214/000095017025096645/sabs-20250717.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-096645
- JSON: https://secwatch.observer/filing/0000950170-25-096645.json
- Plain text: https://secwatch.observer/filing/0000950170-25-096645.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.